Aka AstraZeneca (m.fl)… ser nå at trvx skrev følgende i sin 12mnd meso update:
Recently, at ASCO
2020, results from a first line mesothelioma trial assessing SoC chemotherapy in
combination with the anti-PD-L1 checkpoint inhibitor durvalumab showed a 70% 12
-month survival rate. This suggests that ONCOS-102 alone plus SoC chemotherapy
may already achieve a level of benefit close to that observed with checkpoint
inhibition plus SoC chemotherapy. It is expected that addition of checkpoint
inhibition to ONCOS-102 and Soc will provide even further clinical benefit due
to engagement of distinct and complementary biological mechanisms. As such,
Targovax’s future clinical development of ONCOS-102 will focus on first line
mesothelioma with the triple combination of a checkpoint inhibitor, ONCOS-102
and SoC. A randomized phase II trial is currently being planned in collaboration
with a pharma partner.
Er så bra at Merck er “pharma partner” for AZ vil trolig ikke kunne matche keytruda+oncos+chemo i meso, samtidig så blir de nødt til å ta et valg om veien videre etter fase 2 i peritoneal der de kominerer durva og oncos. 
